3-isopropylindolizine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯并吡啶类
• 英文名称: 3-isopropylindolizine
• 英文别名: 3-Propan-2-ylindolizine
• 化学式: C₁₁H₁₃N
• 分子量: 159.231
• InChiKey: BIFWXRYEDIZMHG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  4.4
• 氢给体数：
  0
• 氢受体数：
  0

反应信息

• 作为反应物：
  描述：

  5-氨基-2-甲氧基吡啶 、 草酰氯 、 3-isopropylindolizine 在 4-二甲氨基吡啶 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 为溶剂， 反应 21.0h， 以66%的产率得到2-(3-isopropylindolizin-1-yl)-N-(6-methoxypyridin-3-yl)-2-oxoacetamide
  参考文献：
  名称：

  An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer

  摘要：

  A number of indole-3-glyoxylamides have previously been reported as tubulin polymerization inhibitors, although none has yet been successfully developed clinically. We report here a new series of related compounds, modified according to a strategy of reducing aromatic ring count and introducing a greater degree of saturation, which retain potent tubulin polymerization activity but with a distinct SAR from previously documented libraries. A subset of active compounds from the reported series is shown to interact with tubulin at the colchicine binding site, disrupt the cellular microtubule network, and exert a cytotoxic effect against multiple cancer cell lines. Two compounds demonstrated significant tumor growth inhibition in a mouse xenograft model of head and neck cancer, a type of the disease which often proves resistant to chemotherapy, supporting further development of the current series as potential new therapeutics.

  DOI：

  10.1021/acs.jmedchem.5b01312
• 作为产物：
  描述：

  4-甲基-1-戊炔 在 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 三乙胺 、 三苯基膦 、 copper(l) chloride 作用下， 以 N,N-二甲基乙酰胺 为溶剂， 反应 25.0h， 生成 3-isopropylindolizine
  参考文献：
  名称：

  An Orally Bioavailable, Indole-3-glyoxylamide Based Series of Tubulin Polymerization Inhibitors Showing Tumor Growth Inhibition in a Mouse Xenograft Model of Head and Neck Cancer

  摘要：

  A number of indole-3-glyoxylamides have previously been reported as tubulin polymerization inhibitors, although none has yet been successfully developed clinically. We report here a new series of related compounds, modified according to a strategy of reducing aromatic ring count and introducing a greater degree of saturation, which retain potent tubulin polymerization activity but with a distinct SAR from previously documented libraries. A subset of active compounds from the reported series is shown to interact with tubulin at the colchicine binding site, disrupt the cellular microtubule network, and exert a cytotoxic effect against multiple cancer cell lines. Two compounds demonstrated significant tumor growth inhibition in a mouse xenograft model of head and neck cancer, a type of the disease which often proves resistant to chemotherapy, supporting further development of the current series as potential new therapeutics.

  DOI：

  10.1021/acs.jmedchem.5b01312

文献信息

• SILICON BASED DRUG CONJUGATES AND METHODS OF USING SAME
  申请人：BlinkBio, Inc.

  公开号：US20170202970A1

  公开（公告）日：2017-07-20

  Described herein are silicon based conjugates capable of delivering one or more payload moieties to a target cell or tissue. Contemplated conjugates may include a silicon-heteroatom core, one or more optional catalytic moieties, a targeting moiety that permits accumulation of the conjugate within a target cell or tissue, one or more payload moieties (e.g., a therapeutic agent or imaging agent), and two or more non-interfering moieties covalently bound to the silicon-heteroatom core.

  本文描述了基于硅的共轭物，能够将一个或多个有效载荷基团传递到靶细胞或组织。考虑到的共轭物可能包括一个硅-杂原子核心，一个或多个可选的催化基团，一个定位基团，允许共轭物在靶细胞或组织内积累，一个或多个有效载荷基团（例如，治疗剂或成像剂），以及与硅-杂原子核心共价结合的两个或更多个不干扰基团。
• HETEROARYLS AND USES THEREOF
  申请人：MILLENNIUM PHARMACEUTICALS, INC.

  公开号：US20130165472A1

  公开（公告）日：2013-06-27

  This invention provides compounds of formula IA: and also provides compounds of formula IIA, IIIA, IVA, or VA: wherein HY, R 1 , R 2 , R 3 , R 14 , G 1 , G 2 , G 3 , and G 4 , are as described in the specification. The compounds are inhibitors of VPS34 and/or PI3K and are thus useful for treating proliferative, inflammatory, or cardiovascular disorders.

  这项发明提供了公式IA的化合物：同时也提供了公式IIA、IIIA、IVA或VA的化合物：其中HY、R1、R2、R3、R14、G1、G2、G3和G4如规范中所述。这些化合物是VPS34和/或PI3K的抑制剂，因此可用于治疗增生性、炎症性或心血管疾病。
• Viral Polymerase Inhibitors
  申请人：TSANTRIZOS Youla S.

  公开号：US20090170859A1

  公开（公告）日：2009-07-02

  An enantiomer, diastereoisomer or tautomer of a compound, represented by formula I: wherein A, B, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , R 9 , and R 10 are as defined herein, or a salt or ester thereof, as an inhibitor of HCV NS5B polymerase.

  一种手性异构体、非对映异构体或互变异构体，由公式I所表示的化合物：其中A、B、R1、R2、R3、R4、R5、R6、R7、R8、R9和R10如本文所定义，或其盐或酯，作为HCV NS5B聚合酶的抑制剂。
• COMPOUNDS FOR TREATMENT OF DRUG RESISTANT AND PERSISTENT TUBERCULOSIS
  申请人：THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH

  公开号：US20160194299A1

  公开（公告）日：2016-07-07

  Described herein are compounds and compositions for treating drug resistant and persistent tuberculosis. Also described herein is a method of screening for identifying biofilm formation inhibitors.
• HETEROARYL COMPOUNDS FOR KINASE INHIBITION
  申请人：ARIAD PHARMACEUTICALS, INC.

  公开号：US20170197962A1

  公开（公告）日：2017-07-13

  Compounds and pharmaceutical compositions that modulate kinase activity, including mutant EGFR and mutant HER2 kinase activity, and compounds, pharmaceutical compositions, and methods of treatment of diseases and conditions associated with kinase activity, including mutant EGFR and mutant HER2 activity, are described herein.